Vabysmo

In January 2022, the U.S. Food and Drug Administration (FDA) approved Vabysmo (faricimab-svoa), making it the first bispecific antibody for the eye. D...

Delivering medications directly into the eye may sound daunting, but for many patients with retinal diseases, intravitreal injections are the most eff...

When it comes to safe and effective medication use, physicians often turn first to the prescribing information (PI)—the official FDA-approved drug lab...

Determining the optimal dosing schedule is one of the most significant challenges in treating retinal diseases. For patients with conditions like neov...

For many people living with retinal diseases, frequent eye injections are a part of treatment. Traditional anti-VEGF therapies often mean monthly clin...

Corticosteroids have been used in eye care for a long time to reduce inflammation and manage conditions such as diabetic macular edema (DME) and other...

Advances in modern eye care have significantly improved the outlook for individuals living with serious vision-threatening conditions. For many years,...

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of vision loss, and managing it often means frequent eye injections. ...

Intravitreal anti-VEGF injections have revolutionized the care of retinal diseases, providing millions of patients with the opportunity to preserve vi...

Intravitreal injections have transformed the way doctors manage retinal conditions, offering hope for diseases that once led to permanent vision loss....